Download PDF
Zentralbl Gynakol 2005; 127(3): 125-131
DOI: 10.1055/s-2005-836407
Übersicht

© Georg Thieme Verlag Stuttgart · New York

Funktion und klinische Bedeutung des Plasminogen-Aktivator-Inhibitors PAI-1 bei gynäkologischen Malignomen. Eine Übersicht[*]

Role of PAI-1 in Gynaecological MalignanciesD. Könsgen1 , A. Mustea1 , W. Lichtenegger1 , J. Sehouli1
  • 1Klinik für Frauenheilkunde und Geburtshilfe, Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin
Further Information

Publication History

Publication Date:
25 May 2005 (online)

    Permissions and Reprints

Zusammenfasssung

Der sog. Plasminogen-Aktivator-Inhibitor PAI-1 steht in den letzten Jahren zunehmend im Fokus der gynäkologischen Onkologie. Der vorliegende Beitrag beleuchtet zum einen die physiologischen und pathophysiologischen Zusammenhänge und diskutiert zum anderen den prognostischen Stellenwert des PAI-1 bei verschiedenen gynäkologischen Malignomen.

Abstract

The plasminogen activator-plasmin cascade plays a central role in tumor cell invasion and metastasis of solid tumors. The type-1 plasminogen activator inhibitor (PAI-1) is the major physiologic regulator of the plasminogen activation. The PAI-1 is suggested to play a crucial role in tumor cell invasion and metastasis of different solid tumors. The aim of this article is to give an overview of the function, clinical and prognostic role of PAI-1 in gynaecological malignancies.

Schlüsselwörter

PAI-I - Ovarialkarzinom - gynäkologische Malignome

Key words

PAI-1 - ovarian cancer - gynaecological malignancies

1 Auszüge aus dem Manuskript wurden auf dem „1. Berliner Symposium: Molekularbiologie in der Gynäkologischen Onkologie - Quo vadis 2004” präsentiert

Literatur

  • 1 Andreasen P A, Georg B, Lund L R, Riccio A, Stacey S N. Plasminogen activator inhibitors: hormonally regulated serpins.  Mol cell Endocrinol. 1990;  68 1-19
    CrossrefPubMedGoogle Scholar
  • 2 Andreasen P A, Kjoller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: a review.  Int J Cancer. 1997;  72 1-22
    CrossrefPubMedGoogle Scholar
  • 3 Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.  Nature. 1976;  261 595-597
    PubMedGoogle Scholar
  • 4 Berger D H. Plasmin/Plasminogen System in Colorectal Cancer.  World J Surg. 2002;  26 767-771
    CrossrefPubMedGoogle Scholar
  • 5 Bouchet C, Hacene K, Martin P M, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer.  J Clin Oncol. 1999;  17 3048-3057
    PubMedGoogle Scholar
  • 6 Cantero D, Friess H, Deflorin J. et al . Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.  Thromb Haemost. 1997;  77 62-70
    PubMedGoogle Scholar
  • 7 Chambers S K, Ivins C M, Carangiu M L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.  Int J Cancer. 1998;  79 449-454
    CrossrefPubMedGoogle Scholar
  • 8 Choong P FM, Anne P W. Urokinase Plasminogen activatot System. A multifunctional role in tumor progression and metastasis.  Clin Orthop Rel Res. 2003;  415 (Suppl) 46-58
    PubMedGoogle Scholar
  • 9 Cubellis M V, Wun T C, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by ist specific inhibitor PAI-1.  EMBO J. 1990;  9 1079-1085
    PubMedGoogle Scholar
  • 10 Danri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A, Perez-Montfort R, Orbach-Arbouys S. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.  Eur J Cancer. 1998;  34 566-569
    CrossrefPubMedGoogle Scholar
  • 11 De Bruin P A, Griffioen G, Verspaget H W. et al . Plasminogen activator profiles in neoplastic tissues of the human colon.  Cancer Res. 1988;  48 4520-4524
    PubMedGoogle Scholar
  • 12 Deng G, Royle G, Seiffert D, Loskutoff D J. The PAI-1/vitronectin interaction: two cats in a bag?.  Thrombosis Haemostasis. 1995;  74 66-70
    PubMedGoogle Scholar
  • 13 Donate L E, Gherardi E, Srinivasav N, Sowdhamini R, Aparicio S, Blundell T L. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP).  Protein Sci. 1994;  3 2378-2394
    PubMedGoogle Scholar
  • 14 Duffy M J, O'Grady P, Devaney D, O'Siorain L, Fennelly J J, Lijnen H J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.  Cancer. 1988;  62 531-533
    PubMedGoogle Scholar
  • 15 Duval-Jobe C, Parmely M J. Regulation of plasminogen activation by human U937 promoocytic cells.  J biol Chem. 1994;  269 21 353-21 357
    PubMedGoogle Scholar
  • 16 Eppenberger U, Kueng W, Schlaeppi J M, Roesel J L, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens J A, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.  J Clin Oncol. 1998;  16 3129-3136
    PubMedGoogle Scholar
  • 17 Ferno M, Bendahl P O, Borg A, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.  Europ J Cancer. 1996;  32 793-801
    CrossrefPubMedGoogle Scholar
  • 18 Foekens J A, Peters H A, Look M P, Portengen H, Schmitt M, Kramer M D, Brunner N, Janicke F, Meijer-van Gelder M E, Henzen-Logmans S C, Putten W L, van Klijn J G. The urokinase system of plasminogen activation and prognosis in 2 780 breast cancer patients.  Cancer Res. 2000;  60 636-643
    PubMedGoogle Scholar
  • 19 Foekens J A, Schmitt M, van Putten W L, Peters H A, Kramer M D, Janicke F, Klijn J G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.  J Clin Oncol. 1994;  12 1648-1658
    PubMedGoogle Scholar
  • 20 Fredstorp-Lidebring M, Bendahl P O, Brunner N, Casslen B, Hogberg T, Langstrom-Einarsson E, Willen R, Ferno M. Urokinase plasminogen activator and ist inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.  Eur J Cancer. 2001;  37 2339-2348
    CrossrefPubMedGoogle Scholar
  • 21 Fujimoto J, Hori M, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria.  Tumour Biol. 1997;  18 13-21
    PubMedGoogle Scholar
  • 22 Ginsburg D, Zeheb R, Yang A Y, Rafferty U M, Andreasen P A, Nielsen L, Dano K, Lebo R V, Gelehrter T D. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.  J Clin Invest. 1986;  78 1673-1680
    CrossrefPubMedGoogle Scholar
  • 23 Gleeson N C, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma.  Cancer. 1993;  72 1670-1672
    CrossrefPubMedGoogle Scholar
  • 24 Grondahl-Hansen J, Christensen I J, Rosenquist C, Brunner N, Mouridsen H T, Dano K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.  Cancer Res. 1993;  53 2513-2521
    PubMedGoogle Scholar
  • 25 Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyl E, Reuning U. Integrin αvβ/Vitronectin Interaction affects expression of the urokinase System in human ovarian cancer cells.  J Biol Chem. 2001;  276 26 340-26 348
    PubMedGoogle Scholar
  • 26 Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsins D and L in primary breast cancer.  Int J Biol Markers. 2000;  15 79-83
    PubMedGoogle Scholar
  • 27 Harbeck N, Kates R E, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.  J Clin Oncol. 2002;  20 1000-1007
    PubMedGoogle Scholar
  • 28 Harbeck N, Schmitt M, Kate R E, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1. Determination in primary breast cancer tissue for individualized therapy concepts.  Clinical Breast Cancer. 2002;  3 196-200
    PubMedGoogle Scholar
  • 29 Hazelbag S, Kenter G G, Gorter A, Fleuren G J. Prognostic relevance of TGF-beta 1 and PAI-1 in cervical cancer.  Int J Cancer. 2004;  112 1020-1028
    CrossrefPubMedGoogle Scholar
  • 30 Herszenyi L, Plebani M, Carraro P. et al . The role of cysteine and serine proteases in colorectal carcinoma.  Cancer. 1999;  86 1135-1142
    CrossrefPubMedGoogle Scholar
  • 31 Hoffmann G, Casper F, Weikel W, Kummerl T, Pollow B, Schaffrat M, Hoffmann M, Pollow K. Value of p53, urokinase plaminogen activator, PAI-1 and Ki-67 in vulvar carcinoma.  Zentralbl Gynakol. 1999;  121 473-478
    PubMedGoogle Scholar
  • 32 Hoffmann G, Pollow K, Weikel W, Strittmatter H J, Bach J, Schaffrath M, Knapstein P, Melchert F, Pollow B. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.  Clin Chem Lab Med. 1999;  37 47-54
    CrossrefPubMedGoogle Scholar
  • 33 Horn L C, Pippig S, Raptis G, Fischer U, Kohler U, Hentschel B, Martin R. Clinical relevance of urokinase-type plasminogen activator and ist inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.  Aust N Z J Obstet Gynaecol. 2002;  42 383-386
    PubMedGoogle Scholar
  • 34 Jänicke F, Prechtl A, Thommsen C. et al . Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type-1.  J Natl Cancer Inst. 2001;  93 913-920
    CrossrefPubMedGoogle Scholar
  • 35 Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase plasminogen activator (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.  Breast Cancer Res Treat. 1993;  24 195-208
    PubMedGoogle Scholar
  • 36 Kim S J, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.  Clin Cancer Res. 1998;  4 177-182
    PubMedGoogle Scholar
  • 37 Klinger K W, Winqvist R, Riccio A, Andreasen P A, Sartorio R, Nielsen L S, Stuart N, Stanislovitis P, Watkins P, Douglas R, Grzeschik K H, Alitalo K, Blasi F, Dano K. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.  Proc Natl Acad Sci USA. 1987;  84 8548-8552
    PubMedGoogle Scholar
  • 38 Knoop A, Andreasen P A, Andersen J A, Hansen S, Laenkholm A V, Simonsen A C, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.  Br J Cancer. 1998;  77 932-940
    CrossrefPubMedGoogle Scholar
  • 39 Kobayasi H, Fujishiro S, Terao T. Impact of urokinase type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.  Cancer Res. 1994;  54 6539-6548
    PubMedGoogle Scholar
  • 40 Köhler U, Hiller R, Martin D. et al . Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.  Gynecol Oncol. 1997;  66 268-274
    CrossrefPubMedGoogle Scholar
  • 41 Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.  Clinical Cancer Research. 2001;  7 1743-1749
    PubMedGoogle Scholar
  • 42 Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.  Gynecol Oncol. 1994;  55 401-409
    CrossrefPubMedGoogle Scholar
  • 43 Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.  Br J Cancer. 1999;  79 1746-1751
    CrossrefPubMedGoogle Scholar
  • 44 Kute T E, Grondahl-Hansen J, Shao S M, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.  Breast Cancer Res Treat. 1998;  47 9-16
    PubMedGoogle Scholar
  • 45 Lauffenburger D. Making connections count.  Nature. 1996;  383 390-391
    CrossrefPubMedGoogle Scholar
  • 46 Liotta L A, Steeg P S, Stetler-Stevenson W G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.  Cell. 1991;  64 327-336
    CrossrefPubMedGoogle Scholar
  • 47 Liu G, Shuman M A, Cohen R L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.  Int J Cancer. 1995;  60 501-506
    PubMedGoogle Scholar
  • 48 Look M P, van Putten W LJ, Duffy M J. et al . Pooled analysis of prognostic impact of u-PA and PAI-1 in 8 377 breast cancer patients.  J Natl Cancer Inst. 2002;  94 116-128
    CrossrefPubMedGoogle Scholar
  • 49 Murphy G, Stanton H, Cowell S. et al . Mechanisms for pro matrix metalloproteinases activation.  APMIS. 1999;  107 38-44
    PubMedGoogle Scholar
  • 50 Naldini L, Vigna E, Bardelli A. et al . Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by stoichiometric reaction.  J Biol Chem. 1995;  270 603-611
    CrossrefPubMedGoogle Scholar
  • 51 Nekarda H, Siewert J, Schmitt M and Ulm K. Tumor-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer.  Lancet. 1994;  343 117
    CrossrefPubMedGoogle Scholar
  • 52 Nykjaer A, Conese M, Christensen E I, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of uPA: Serpin complexes.  EMBO J. 1997;  16 2610-2620
    CrossrefPubMedGoogle Scholar
  • 53 Oka T, Ishida T, Nishino T, Sugimachi K. Immunhistochemical evidence for urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma.  Cancer Res. 1991;  51 3522-3525
    PubMedGoogle Scholar
  • 54 Park J E, Keller G A, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.  Mol Biol Cell. 1993;  4 1317-1326
    CrossrefPubMedGoogle Scholar
  • 55 Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen H H, Dano K, Brünner N. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma.  Cancer Res. 1994;  54 120-123
    PubMedGoogle Scholar
  • 56 Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof E KO, Lijnen H R, Burtin P. The plasminogen-activation system in ovarian tumors.  Int J Cancer. 1993;  55 27-31
    PubMedGoogle Scholar
  • 57 Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Janicke F, Loning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix.  J Pathol. 1999;  189 245-250
    PubMedGoogle Scholar
  • 58 Saito K, Nagashima M, Itawa M. et al . The concentration of tissue plasminogen activator and urokinase in plasma and tissue of patients with ovarian and uterine tumors.  Thromb Res. 1990;  58 355-366
    CrossrefPubMedGoogle Scholar
  • 59 Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.  Cancer Res. 1995;  55 3958-3963
    PubMedGoogle Scholar
  • 60 Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridmann R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.  Clin Cancer Res. 2001;  7 2396-2404
    PubMedGoogle Scholar
  • 61 Schmitt M, Harbeck N, Thomsson C. et al . Clinical impact of plasminogen activation system in tumour invasion and metastasis: Prognostic relevance and target for therapy.  Thromb Haemost. 1997;  78 285-296
    PubMedGoogle Scholar
  • 62 Sheng S. The urokinase-type plaminogen activator system in prostate cancer metastasis.  Cancer and Metastasis Reviews. 2001;  20 287-296
    CrossrefPubMedGoogle Scholar
  • 63 Skelly M M, Troy A, Duffy M J. et al . Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.  Clin Cancer Res. 1997;  3 1837-1840
    PubMedGoogle Scholar
  • 64 Stefansson S, Lawrence D A. The serpin PAI-1 inhibits cell migration by blocking intergrin αvβ3 binding to vitronectin.  Nature. 1996;  383 441-443
    CrossrefPubMedGoogle Scholar
  • 65 Sweep C G, Geurts-Moespot J, Grebenschikov N, de Witte J H, Heuvel J J, Schmitt M, Duffy M J, Janicke F, Kramer M D, Foekens J A, Brunner N, Brugal G, Pedersen A N, Benraad T J. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.  Br J Cancer. 1998;  78 1434-1441
    PubMedGoogle Scholar
  • 66 Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini P G, D'Ambrogio G, Genazzani A R. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.  J Exp Clin Cancer Res. 2001;  20 239-246
    PubMedGoogle Scholar
  • 67 Tecimer C, Doering D L, Goldsmith L J, Meyer J S, Abdulhay G, Wittliff J L. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.  Int J Gynecol Cancer. 2000;  10 372-381
    CrossrefPubMedGoogle Scholar
  • 68 Tecimer C, Doering D L, Goldsmith L J, Meyer J S, Abdulhay G, Wittliff J L. Clinical relevance of urokinase-type plasminogen activator, its receptor, its inhibitor type 1 in endometrial cancer.  Gynecol Oncol. 2000;  80 48-55
    PubMedGoogle Scholar
  • 69 Van der Burg M EL, Henzen-Logmans S C, Berns E MJJ, Putten W LJ, van Klijn J GM, Foekens J A. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.  Int J Cancer (Pred Oncol). 1996;  69 475-479
    CrossrefPubMedGoogle Scholar
  • 70 Vassalli J D, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.  J Cell Biol. 1985;  100 86-92
    CrossrefPubMedGoogle Scholar
  • 71 Wang S N, Miyauchi M, Koshikawa N. et al . Antigen expression associated with lymph node metastasis in gastric adenocarcinomas.  Pathol Int. 1994;  44 844-849
    PubMedGoogle Scholar

1 Auszüge aus dem Manuskript wurden auf dem „1. Berliner Symposium: Molekularbiologie in der Gynäkologischen Onkologie - Quo vadis 2004” präsentiert

D. Könsgen

Klinik für Frauenheilkunde und Geburtshilfe · Campus Virchow-Klinikum · Charité Universitätsmedizin

10117 Berlin

Phone: 0 30/4 50 56 40 52

Fax: 0 30/4 50 56 49 52